LMR Partners LLP Has $1.11 Million Stock Holdings in Inari Medical, Inc. (NASDAQ:NARI)

LMR Partners LLP lessened its holdings in Inari Medical, Inc. (NASDAQ:NARI - Free Report) by 45.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 26,861 shares of the company's stock after selling 22,590 shares during the quarter. LMR Partners LLP's holdings in Inari Medical were worth $1,108,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in NARI. GAMMA Investing LLC lifted its holdings in shares of Inari Medical by 164.7% during the second quarter. GAMMA Investing LLC now owns 704 shares of the company's stock valued at $34,000 after acquiring an additional 438 shares during the period. Nisa Investment Advisors LLC grew its stake in Inari Medical by 83.5% during the second quarter. Nisa Investment Advisors LLC now owns 956 shares of the company's stock worth $46,000 after buying an additional 435 shares during the last quarter. KBC Group NV increased its holdings in shares of Inari Medical by 39.0% during the third quarter. KBC Group NV now owns 1,774 shares of the company's stock worth $73,000 after buying an additional 498 shares in the last quarter. Covestor Ltd raised its stake in shares of Inari Medical by 30.2% in the first quarter. Covestor Ltd now owns 1,619 shares of the company's stock valued at $78,000 after acquiring an additional 376 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. boosted its holdings in shares of Inari Medical by 39.4% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company's stock worth $89,000 after acquiring an additional 522 shares in the last quarter. Institutional investors and hedge funds own 90.98% of the company's stock.

Inari Medical Trading Down 3.9 %

Shares of NASDAQ:NARI traded down $1.97 during mid-day trading on Wednesday, reaching $49.00. The stock had a trading volume of 641,559 shares, compared to its average volume of 985,745. The firm has a 50 day simple moving average of $45.45 and a two-hundred day simple moving average of $47.17. The firm has a market cap of $2.87 billion, a PE ratio of -37.76 and a beta of 0.96. Inari Medical, Inc. has a twelve month low of $36.73 and a twelve month high of $67.13.

Analyst Ratings Changes

A number of equities analysts have commented on NARI shares. Leerink Partnrs raised Inari Medical to a "hold" rating in a research note on Tuesday, September 3rd. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Inari Medical in a research note on Friday, August 9th. They set a "buy" rating and a $68.00 price target on the stock. Needham & Company LLC reiterated a "hold" rating on shares of Inari Medical in a research report on Tuesday, October 29th. Piper Sandler upped their price target on Inari Medical from $50.00 to $52.00 and gave the company a "neutral" rating in a research note on Tuesday, October 29th. Finally, William Blair assumed coverage on Inari Medical in a research report on Thursday, July 25th. They issued an "outperform" rating for the company. Six investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $58.89.

Insider Activity at Inari Medical

In other Inari Medical news, Director William Hoffman sold 60,000 shares of the firm's stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $51.16, for a total transaction of $3,069,600.00. Following the sale, the director now directly owns 501,233 shares in the company, valued at approximately $25,643,080.28. This trade represents a 10.69 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Andrew Hykes sold 3,000 shares of the company's stock in a transaction that occurred on Tuesday, October 29th. The shares were sold at an average price of $50.00, for a total transaction of $150,000.00. Following the completion of the transaction, the chief executive officer now owns 445,310 shares of the company's stock, valued at $22,265,500. This trade represents a 0.67 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 186,000 shares of company stock worth $8,990,990 in the last quarter. Corporate insiders own 10.60% of the company's stock.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.